Nasser, Azmi F.

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

Johnson, J. K., Liranso, T., Saylor, K., Tulloch, G., Adewole, T., Schwabe, S., Nasser, A., Findling, R. L., & Newcorn, J. H. (2020) · Journal of Attention Disorders

Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices

Cited by 62

Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status

Findling, R. L., Candler, S. A., Nasser, A. F., Schwabe, S., Yu, C., Garcia-Olivares, J., O’Neal, W., & Newcorn, J. H. (2021) · CNS Drugs

Attention Deficit Hyperactivity DisorderTreatment of Major Depression

Cited by 55

A model‐based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP‐7000, a new, long‐acting, sustained‐released formulation of risperidone

Gomeni, R., Heidbreder, C., Fudala, P. J., & Nasser, A. F. (2013) · The Journal of Clinical Pharmacology

Schizophrenia research and treatmentPharmaceutical studies and practices

Cited by 38

Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment

Laffont, C. M., Gomeni, R., Zheng, B., Heidbreder, C., Fudala, P. J., & Nasser, A. F. (2014) · Clinical Pharmacokinetics

Schizophrenia research and treatmentPharmaceutical studies and practices

Cited by 35

Population pharmacokinetic modeling and simulation to guide dose selection for RBP‐7000, a new sustained‐release formulation of risperidone

Laffont, C. M., Gomeni, R., Zheng, B., Heidbreder, C., Fudala, P. J., & Nasser, A. F. (2015) · The Journal of Clinical Pharmacology

Schizophrenia research and treatmentPharmaceutical studies and practices

Cited by 26